Serán BioScience, has finished the expansion of its clinical manufacturing facility in Bend, Oregon.
The site now has 14 process manufacturing suites, meaning its cGMP clinical manufacturing capacity has increased by approximately 130%.
The eight additional suites will enhance the company's small molecule production capability, which will mainly supply pharmaceutical companies with medications for late-stage clinical trials.
Serán’s ‘Right-From-the-Start’ approach will include API bioavailability enhancement services, as well as matrix tablet and multiparticulate-based modified release and capsule & immediate/modified release tablet capabilities.
The company can also produce engineered particles designed for incorporation into inhaled drug products.
The novel sections of the facility are located within the existing footprint of Serán BioScience's campus in Bend, which spans 90,000 sqft.
“Serán continues to see high demand for science-based drug product services,” commented Serán's President and CEO, Dan Smithey.
“We are excited to announce the expansion at the site, where we can now provide mid- and large-scale manufacturing unit operations to support our clients’ journey from first-in-human studies through to pivotal trials and registration.”
